Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an <i>FGFR2</i> gene fusion or rearrangement.

Milind Javle, Ghassan K. Abou‐Alfa, Wei Peng Yong et al.|Journal of Clinical Oncology|2021

Cited by 86